A group of 51 patients with multiple myeloma, nonHodgkin's lymphoma or Hodgkin's disease receiving high-dose chemotherapy and autologous peripheral blood stem cell rescue received chemotherapy and clinical care in the peritransplant period at home. This group was compared with 88 cases with the same diagnoses, receiving the peripheral stem cell transplant over the same time period as an inpatient in a high efficiency particulate air filtered bone marrow transplant unit. Patients were treated at home based on choice, geographic accessibility, availability of an educated care giver and a clean home environment, and comprehension of the concepts of infection and aseptic techniques. Febrile neutropenia and sepsis were not increased in the home group and no episodes of septic shock were seen in this group. Patients at home received prophylactic oral ciprofloxacin and roxithromycin during the phase when the absolute neutrophil count was Ͻ1 × 10 9 /l. Fewer gram-negative infections, but no diminution in gram-positive infections or in the rate of fever were seen in patients at home. Empiric therapy with a third generation cephalosporin, teicoplanin and tobramycin was instituted in 31 patients who developed a fever greater than 38.5؇C. Of this group of 31, 18 required admission to hospital, 12 because of febrile neutropenia which persisted or was considered unsuitable for management at home due to sepsis. The remaining 13 with febrile neutropenia remained at home throughout, as did the 20 cases not developing neutropenic fever. This study demonstrates the feasibility of managing carefully selected patients in their home environment when at risk from febrile neutropenia or other septic complications following autologous peripheral stem cell support. Keywords: autologous stem cell transplantation; home; infection; myeloma; lymphoma 
ondary to their underlying neoplasm and the immunosuppressive side-effects of previous cytotoxic chemotherapy. 1 To date, most bone marrow transplants have been carried out in hospital in the environment of a dedicated Bone Marrow Transplant Unit (BMTU). Such units usually have single rooms with ensuite facilities and high efficiency particulate air (HEPA)-filtered air circulation. Increasingly, HSCTs have been carried out on an outpatient basis. 2, 3 In 1995 we began a programme of clinical care in the patient's home for patients undergoing HSCT. 4 This involved a multidisciplinary team consisting of an oncology/haematology trained clinical nurse on rotation from the BMTU, BMTU physician, a home care giver who was usually a relative of the patient, a hospital-based pharmacist, a hospital-based dietitian and the BMTU nursing staff for after hours advice.
While most bacterial and fungal infections in this group of patients are caused by micro-organisms arising from the skin, upper and lower gut and respiratory tract, we were concerned that other infections may be occurring from the environment at home outside the protection of a HEPAfiltered BMTU environment. We therefore undertook a study of the infections experienced in a group of 51 patients receiving HSCT at home for non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD) or multiple myeloma (MM) and compared this group with 81 patients undergoing HSCT in the BMTU over the same time period for NHL, HD and MM.
Methods

Requirements
Eligibility to undertake HSCT at home included: (1) patient desire; (2) geographic accessibility -the patient needed to be within 45 min travelling time of the BMTU; (3) a care giver usually a close relative, who was available 24 h a day, able to be educated by the clinical nurse in supporting the patient; (4) a clean environment and both the patient and care giver able to understand the concepts of infection, sterility and sterile environment; (5) emotional stability of the patient and care giver; and (6) good performance status (ECOG 0, 1 or 2).
Patients studied
Patient characteristics are shown in Table 1 . The patients all had recurrent lymphoma or myeloma after primary therapy and were offered HSCT after one or more courses of salvage therapy that produced tumour cytoreduction. Excluded from this study were: (1) patients given chemotherapy in hospital and discharged for care at home; and (2) patients receiving HSCT for solid tumour or leukaemia due to small numbers being cared for at home.
Detailed clinical management plans for patients at home have previously been described. 4 The clinical nurse visited the patient once or twice daily depending on necessity, carried out clinical assessment, administered chemotherapy or other care procedures at home, took appropriate blood samples which were taken back to the laboratory for analysis. A conference was held between the nurse and other members of the team, and decisions made in the light of the clinical findings and blood test parameters. The home nurse was not available at night and the BMTU nursing staff were appraised of the patient's condition, the carer being instructed to ring the BMTU if there were any concerns at night.
Patients managed at home received haemopoietic stem cell infusions in a hospital day care facility as outpatients. Platelet and blood transfusions when required were given in the day care unit.
Inpatients were managed in the BMTU with 10 single HEPA-filtered rooms with ensuite bathroom and toilet facilities. The diet was food freshly cooked, with no uncooked food. Regular microbiological monitoring of the room air, tap and shower water was undertaken.
Chemotherapy protocols
Patients with myeloma received methylprednisolone 1 g/m 
Antibiotic prophylaxis
All inpatients received norfloxacin 400 mg twice daily by mouth (p.o.) from the start of the conditioning chemotherapy until granulocyte recovery to an absolute neutrophil count (ANC) 1 × 10 9 /l and those treated at home received ciprofloxacin 750 mg twice daily p.o. and roxithromycin 300 mg once daily p.o. when the total white cell count (WCC) fell below 1 × 10 9 /l. Prophylactic fluconazole 200 mg orally once daily was used in all patients.
Management of complications at home
A set of algorithms was drawn up for management of common complications, which were refined over time. 4 If febrile neutropenia occurred the clinical nurse initially made a decision in consultation with the BMTU physician concerning the patient's condition. The patient was admitted to hospital if clinically indicated, eg hypotension, severe diarrhoea. Blood and urine cultures were taken by the nurse prior to initiating empiric therapy with cefpirome 1 g i.v. twice daily, teicoplanin 400 mg i.v. once daily, and tobramycin 5 mg/kg i.v. once daily.
If the patient's fever responded, the patient was continued on treatment at home. However, if the patient's condition did not respond or there was deterioration, the patient was admitted to hospital.
Management of complications in hospital
The same algorithms were used for inpatient management, however, febrile neutropenia was managed differently, in that a glycopeptide was not routinely commenced if the patient was not hypotensive or severely ill. After blood and urine cultures, antibiotic therapy with ceftazidime 1 g i.v. three times daily, and tobramycin 5 mg/kg i.v. once daily was started. If there was no response over 24 h or if there was clinical suggestion of gram-positive sepsis, eg erythema at the entry site of the central venous catheter, then vancomycin 15 mg/kg i.v. twice daily was started additionally. Vancomycin and tobramycin dose was varied according to renal function and drug assays.
Complications were graded using Miller's formula. 5 
Statistical methods
The Kaplan-Meier method was used to determine overall survival rate. 6 Breslow's statistic was used to evaluate statistical significance for overall and disease-free survival across the location (domiciliary/hospital) groups. 7 The difference in means between location groups for all continuous data were calculated by t-test for differences of the mean. 8 The probability for ordinal data was measured by the Mann-Whitney U test. 
Results
Fever Ͼ38.5°C
For NHL no significant difference was seen between inpatients and patients treated at home (Figure 1 ). Thirty-nine percent of those at home and 42% of those in hospital experienced no fever Ͼ38.5°C (P = 0.72). A mean of 2.0 Ϯ 0.61 days of fever Ͼ38.5°C was seen in those at home compared with 2.36 Ϯ 0.48 for those in hospital.
For multiple myeloma there was no significant difference between fever in hospital compared with at home (Figure 2 ). Forty-one percent of those at home experienced no fever compared with 45% in hospital. A mean of 1.23 Ϯ 0.41 days of fever Ͼ38.5°C was seen in those at home compared with 1.46 Ϯ 0.51 for those in hospital (P = 0.72). Also for Hodgkin's disease there was no difference between those in hospital and those at home, with a mean of 0.57 Ϯ 0.3 days Ͼ38.5°C for those at home and 0.53 Ϯ 0.23 days for those in hospital.
Intravenous antibiotic therapy
For non-Hodgkin's lymphoma a mean of 8.72 Ϯ 1.20 days of antibiotic therapy was given to those on the home programme compared with 9.91 Ϯ 0.73 for those in hospital (P = 0.39) (Figure 3) .
Similarly, for multiple myeloma there was no significant difference in the number of days of intravenous antibiotics given. A mean of 8.62 Ϯ 1.16 days was required for those at home compared with a mean of 8.32 Ϯ 0.84 for those in hospital (P = 0.84) (Figure 4 ).
Microbial isolates in febrile patients
In 61% of patients at home no organism was identified, compared with 55% of the inpatient population. The classes of organisms identified are shown in Figure 5 , and detailed in Table 2 . Of note, there were two isolates of respiratory syncitial virus in the domiciliary group, although one patient had been admitted to hospital for 14 days before this developed. Herpes simplex virus was isolated from two inpatients.
Other complications
There was no significant difference in diarrhoea with 53% of the domiciliary and 58% of the hospital patients experiencing grade 2-3 diarrhoea. Following BEAM conditioning, significantly less mucositis was seen in patients treated at home compared with inpatients, with none of the home patients experiencing grade III-IV mucositis compared with 42% of inpatients ( Figure 6 ). Mucositis was less of a problem in myeloma with no difference seen between inpatients and those at home.
Admission to hospital
Eighteen of the home patients required admission to hospital with a median of 3 days (range 1-33). The primary reasons for admission to hospital were febrile neutropenia (12) diarrhoea (four) and nausea and vomiting (two).
Survival
There were two toxic deaths in the home group. One was a patient with myeloma with dialysis-dependent renal failure who was admitted on day +7 with febrile neutropenia and who subsequently developed respiratory syncitial virus pneumonia and died of respiratory failure on day +35. The other was a male with advanced NHL, aged 48 who engrafted by day +11 but who was subsequently admitted on day +43 with Candida glabrata pneumonia and died on day +70 after multi-organ failure supervened.
Discussion
The incidence of gram-positive organisms was similar in home compared with hospital patients ( Figure 5 ) but slightly more gram-negative infections were seen in the inpatients who were not receiving ciprofloxacin prophylaxis (12% compared with 6%) and similar small numbers of viral and fungal infections were seen in both home and hospital patients. No organism was identified in the majority of patients, as was expected. The percentage of patients requiring intravenous antibiotic therapy was similar in both groups implying that prophylactic therapy did not prevent fever. However, prophylaxis with ciprofloxacin appeared to abolish serious gram-negative infections in the domiciliary patients. Several serious pseudomonas infections were seen in inpatients. The predominant grampositive organism cultured was coagulase-negative staphylococcus in both groups of patients, associated with the use of central venous cannulas. There was no increase in infections in the patients treated at home despite the lack of HEPA-filtered accommodation.
In carefully selected patients the home environment appears to be appropriate for those undergoing autologous PBPC transplantation. Sicker patients preferred the security and increased nursing support of the BMTU environment. The higher rate of mucositis seen following BEAM conditioning in inpatients reflects the poorer clinical status of these patients.
The Infectious Disease Society of America has produced guidelines for the therapeutic use of antimicrobial agents in neutropenic patients with unexplained fever and recommendations for prophylactic antibiotic therapy in the neutropenic setting. 9 Recommendations for prophylaxis recognised the difficulty in prevention of fever and the current concern about emergence of antibiotic-resistant bacteria due to misuse of antibiotics. An analysis of prophylactic therapy showed that no prophylactic antibiotic regimen has been found to reduce the mortality rate, although the infection rate is reduced. The recommendations were that prophylactic antibiotic therapy be considered on a case by case basis and that the period of antibiotic therapy should be as brief as possible. In our patients we considered that the risk of rapidly overwhelming gram-negative bacterial sepsis in the patient outside of hospital was serious enough to warrant the use of quinolone prophylaxis. To diminish the length of time on prophylactic antibiotic therapy we waited until documented severe neutropenia developed, maintaining prophylactic therapy only while the absolute neutrophil count was Ͻ1 × 10 9 /l but utilising therapeutic doses. The brief period of neutropenia seen after peripheral blood stem cell support compared with bone marrow has facilitated a briefer duration of antibiotic prophylaxis.
While it is reasonable to treat patients with febrile neutropenia with empirical monotherapy using broad-spectrum third generation cephalosporin or carbapenem 10 we chose to use therapy at home with a cephalosporin, an aminoglycoside and a glycopeptide to obtain maximal response as fast as possible, given the lack of 24 h nursing and medical surveillance in the patients at home. This policy may have avoided a number of hospital admissions but drug costs were greater as it involved use of more expensive antibiotics, chosen to be given at a less frequent interval, eg teicoplanin once daily by intravenous bolus instead of vancomycin twice daily by infusion with the need for vancomycin assays.
Others have used intravenous antibiotics followed by oral quinolone therapy after response for the treatment of neutropenic fever in similar episodes. 11 In changing to oral ciprofloxacin there is a small percentage of failures.
The question of haemopoietic recovery being influenced by antimicrobial prophylaxis has been raised. Two studies comparing ciprofloxacin with cotrimoxazole have demonstrated that there is delayed recovery using cotrimoxazole whereas ciprofloxacin has no impact on recovery. 12, 13 In undertaking clinical care at home for patients at risk for febrile neutropenia and other septic and metabolic complications in the peritransplant period, a highly motivated multidisciplinary team is pivotal in ensuring success of such a programme, and requires close collaboration in the management of these patients.
